The University of Chicago Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Cohen, Ezra
One or more keywords matched the following items that are connected to Cohen, Ezra
Item TypeName
Concept Vascular Endothelial Growth Factor Receptor-2
Concept Vascular Endothelial Growth Factor Receptor-3
Concept Receptors, Vascular Endothelial Growth Factor
Concept Vascular Endothelial Growth Factor A
Concept Vascular Endothelial Growth Factor Receptor-1
Academic Article Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
Academic Article Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Academic Article New approaches to thyroid cancer.
Academic Article Novel molecular targeted therapies for refractory thyroid cancer.
Academic Article Targeting angiogenesis in head and neck cancer.
Academic Article Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors.
Academic Article Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
Academic Article Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.
Academic Article Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.
Academic Article Pharmacokinetics of single-agent axitinib across multiple solid tumor types.
Academic Article A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.
Academic Article Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.
Academic Article Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.
Academic Article A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
Search Criteria
  • Endothelial Growth Factors